Navigation Links
Gene-Eden-VIR Has Best Value; polyDNA Compares Treatments for HPV Infection
Date:4/29/2013

//sanevax.org/glaxosmithkline-drops-the-price-of-cervarix/" onclick="linkClick(this.href)">http://sanevax.org/glaxosmithkline-drops-the-price-of-cervarix/
(6)    http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php
(7)    gene-eden-kill-virus.com/studies.php

###

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10666360.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Gene-Eden-VIR is Most Cost Effective; polyDNA Compares Treatments for Herpes Infection
2. GYT and Take Gene-Eden-VIR; polyDNA Recommends an HPV Remedy to Infected Individuals
3. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
4. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
5. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
6. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
7. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
8. Lung Cancer Survivors Share Stories of Value of Early Detection and Hope for More Effective Treatments
9. Only 16% of Donations go to New Cancer Treatments in Some Charities. With cureLauncher, 91% of Contributions Go Directly to New Cures for Cancer.
10. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
11. Bacterias hidden skill could pave way for stem cell treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Arlington, VA (PRWEB) October 31, 2014 ... safety and sustainability consultancy, announced today that Dr. ... a Principal Consultant and will work closely with ... Clewell will also continue to serve at The ... Research Triangle Park, North Carolina, where he is ...
(Date:10/30/2014)... Investor-Edge has initiated coverage on ... Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. ... MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free ... http://investor-edge.com/register . On Wednesday, October 29, ... the Dow Jones Industrial Average declined 0.18%, to finish ...
(Date:10/30/2014)... MA (PRWEB) October 30, 2014 ... and collaboration provider, offers Office 365 end users ... into a complete phone system by adding voice ... 365 (O365) includes Lync Online, a communication tool ... Lync calls. With hosted voice, O365 becomes a ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Avure Technologies celebrates ... 525L, the newest member of its fleet of high volume ... reaching an anniversary as we return to PackExpo this year, ... ago in Las Vegas,” said Jeff Williams, CEO at Avure. ... and we’re pleased to be meeting the challenges of market ...
Breaking Biology Technology:Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... Inc.,(Nasdaq: VSCP ), a leading provider of ... 25, 2009 it will release its 2008,fourth quarter and ... 2008. The company will host a conference call ... 11:00 a.m. EST. , VirtualScopics, ...
... Include: - Initiation of development activities to ... Receipt of GRAS (Generally Recognized As Safe) ... commercialization in the U.S. and elsewhere- New ... Continued activities to support regulatory filings for ...
... LAIYANG, China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... pharmaceutical company with its principal operations,in the People,s Republic ... conference call at 9:00 a.m. Eastern on Tuesday, February ... ended December 31, 2008 of,its fiscal year 2009. , ...
Cached Biology Technology:VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement 2VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 2SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 3SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 4SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 5SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 6SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 7SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 8SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 9SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 10SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 11SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 12SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 13SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS 14Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 2Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 3
(Date:10/30/2014)... DALLAS , Oct. 29, 2014 /PRNewswire/ ... and criminal justice technology solutions for public ... that it has deployed exciting enhancements to ... data analytics to provide actionable intelligence and ... Technologies continues to drive technological innovation through ...
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
... in Biomed Central,s open access journal Journal of ... brain to develop Alzheimer,s disease. To date ... of inflammation in Alzheimer,s disease (AD), especially because trials ... ADAPT (The Alzheimer`s Disease Anti-inflammatory Prevention Trial) trial was ...
... Physics World, Steve Haake, director of the Centre for Sports ... the men,s 100 m sprint will be one event not ... the "performance-improvement index", which uses very simple physics to compare ... the last 100 years. The model shows that the ...
... next "next-gen" technology in genome sequencing has gotten a major ... Spring Harbor Laboratory (CSHL) and collaborators today published results of ... was recently introduced but whose use has so far been ... CSHL Assistant Professor Michael Schatz and Adam Phillippy and Sergey ...
Cached Biology News:Physics confirms sprinters are performing better than ever before 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 3
... The new D-LUX Detection Platform ... to provide the most sensitive, specific, ... qPCR. Invitrogens D-LUX Detection Platform offers ... equal to TaqMan probes, high signal/background ...
Provides continuous mixing action. For use with tubes, vials, and other containers...
... is aseptically collected via cardiac puncture from 3 ... mixed sex). It is then centrifuged and frozen ... filtered and bottled at 4C then stored at ... HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU CAN NOW ...
Modified and insect cell culture tested....
Biology Products: